Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza<sup>&#174;</sup>), but a significant proportion of patients are...

Full description

Bibliographic Details
Main Authors: Thomas Cluzeau, Nathan Furstoss, Coline Savy, Wejdane El Manaa, Marwa Zerhouni, Lauriane Blot, Anne Calleja, Maeva Dufies, Alix Dubois, Clemence Ginet, Nicolas Mounier, Georges Garnier, Sophie Raynaud, Pierre Simon Rohrlich, Pierre Peterlin, Aspasia Stamatoullas, Fatiha Chermat, Pierre Fenaux, Arnaud Jacquel, Guillaume Robert, Patrick Auberger
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:International Journal of Molecular Sciences
Subjects:
acadesine
azacitidine
apoptosis
mds
aml
phase i/ii clinical trial
Online Access:https://www.mdpi.com/1422-0067/21/1/164

Internet

https://www.mdpi.com/1422-0067/21/1/164

Similar Items